Aditxt, Inc.

ADTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-43.1M $-40.4M $-32.7M $-27.6M $-46.4M $-9.1M $-5.8M
Depreciation & Amortization
Depreciation $269.3K $613.9K $435.0K $429.0K $369.2K $17.8K $0
Amortization $3.3K $3.3K $107.6K $107.0K $107.0K
Stock-Based Compensation $473.3K $33.1K $1.4M $3.1M $4.6M $3.2M $3.7M
Net Cash from Operating Activities $-25.7M $-16.8M $-19.2M $-22.4M $-22.3M $-7.2M $-464.4K
Investing Activities
Capital Expenditures $13.7K $14.4K $367.1K
Business Acquisitions $70.0K
Net Cash from Investing Activities $-2.4M $-5.0M $-14.4K $-241.9K $-16.3M $-170.6K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $30.5M $22.5M $16.5M $17.5M $36.0M $17.9M $352.7K
Net Change in Cash $-5.1M $-2.6M $10.5M $-111.6K
Free Cash Flow $-25.7M $-19.2M $-22.8M